Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PPSGG (PN-1007) in Anti-MAG Neuropathy Patients

Next Previous
Trial Profile

First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PPSGG (PN-1007) in Anti-MAG Neuropathy Patients

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 19 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PN 1007 (Primary)
  • Indications Demyelinating disorders; Paraproteinaemia
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Polyneuron Pharmaceuticals

Most Recent Events

  • 07 Oct 2021 Status changed from suspended to discontinued (Data don't support further development)
  • 11 Feb 2021 Status changed from recruiting to suspended as initial clinical data require further evaluation.
  • 26 Oct 2020 Planned initiation date changed from 1 Sep 2020 to 1 Oct 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top